Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.


BACKGROUND The direct thrombin inhibitor bivalirudin has been found to be noninferior to heparin plus planned glycoprotein (GP) IIb/IIIa blockade in the prevention of acute ischemic end points and 1-year mortality after percutaneous coronary intervention (PCI) with bare metal stents. We investigated whether long-term outcomes after bivalirudin use remained… (More)


  • Presentations referencing similar topics